Ryan Haumschild, PharmD, MS, MBA, engages in a discussion about the role of precision medicine and targeted therapies in the context of metastatic colorectal cancer (mCRC). John L. Marshall, MD, provides insights into the current status and future potential of precision medicine.

Dr Marshall emphasizes that the field of precision medicine is still in its adolescence, highlighting the challenges that oncologists face in interpreting genetic test results. He points out that the field is rapidly evolving and the technology for genetic testing is constantly improving. He acknowledges that we still have much to learn about the genetic drivers of colorectal cancer and the various pathways involved. Additionally, he touches on the emerging role of multiomics testing, which explores not only genes but also RNA, proteins, and phosphorylated proteins to better understand the pathways driving cancer.

Ben George, MD, agrees with Dr Marshall’s points and highlights the complexity of colorectal cancer biology. He emphasizes that it is no longer sufficient to think of cancer as a straightforward process with a single target, given the tumor’s dynamic nature and interactions with factors such as the microenvironment, the immune system, and the microbiome. He points out the challenge of comprehensively addressing these complex interactions and the need for more computing power and bioinformatic expertise.

David Fenstermacher, PhD, underscores the importance of biomarker testing in precision medicine. He notes that although academic medical centers and comprehensive cancer centers conduct biomarker testing as part of their standard of care, many patients with colorectal cancer across the country do not receive comprehensive biomarker testing. He emphasizes the need to ensure that all patients have access to these tests, both for personalized care and future research.

Dr Haumschild adds to the discussion by emphasizing the importance of broad testing panels not only for current clinical use but also for future research. Having comprehensive patient evaluations and data on patient sensitivity to various treatments can inform and advance future research efforts.

The dialogue highlights the challenges and opportunities in the field of precision medicine for metastatic colorectal cancer and the need for broader testing and better understanding of the genetic and molecular drivers of this disease.

Video synopsis is AI-generated and reviewed by AJMC editorial staff.